Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Gyre Therapeutics (GYRE) EBIAT (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed EBIAT for 16 consecutive years, with -$1.3 million as the latest value for Q4 2025.

  • Quarterly EBIAT fell 331.99% to -$1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 million through Dec 2025, down 44.54% year-over-year, with the annual reading at $9.9 million for FY2025, 44.8% down from the prior year.
  • EBIAT for Q4 2025 was -$1.3 million at Gyre Therapeutics, down from $5.9 million in the prior quarter.
  • The five-year high for EBIAT was $51.6 million in Q2 2022, with the low at -$101.0 million in Q4 2023.
  • Average EBIAT over 5 years is -$7.1 million, with a median of $1.1 million recorded in 2024.
  • The sharpest move saw EBIAT plummeted 453.61% in 2021, then surged 359.09% in 2022.
  • Over 5 years, EBIAT stood at -$20.3 million in 2021, then crashed by 37.23% to -$27.9 million in 2022, then tumbled by 261.95% to -$101.0 million in 2023, then surged by 100.56% to $569000.0 in 2024, then tumbled by 331.99% to -$1.3 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$1.3 million, $5.9 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.